MASON, Ohio --(BUSINESS WIRE)--Jan. 4, 2024-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board
MASON, Ohio --(BUSINESS WIRE)--Dec. 20, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the
MASON, Ohio --(BUSINESS WIRE)--Nov. 15, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the
MASON, Ohio --(BUSINESS WIRE)--Nov. 14, 2023-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023
Worldwide revenue of $98.3 million – an increase of 18.1% year over year U.S. revenue of $81.7 million – an increase of 17.1% year over year International revenue of $16.6 million – an increase of 23.2% year over year Net loss of $9.1 million – an improvement of $3.2 million year over year Positive
MASON, Ohio --(BUSINESS WIRE)--Oct. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the
MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvement of $9.7 million year over year
MASON, Ohio --(BUSINESS WIRE)--Jul. 21, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
MASON, Ohio --(BUSINESS WIRE)--Jul. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter
Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improvement of $8.7 million year over year Positive
MASON, Ohio --(BUSINESS WIRE)--Apr. 19, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an
MASON, Ohio --(BUSINESS WIRE)--Apr. 11, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter
MASON, Ohio --(BUSINESS WIRE)--Apr. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year 2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year 2022 International revenue of $53.2 million – an increase of 17.7% in 2022 MASON, Ohio --(BUSINESS WIRE)--Feb. 21, 2023-- AtriCure, Inc.
